$14.14
5.04% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US14179K1016
Symbol
CRGX
Sector
Industry

CARGO Therapeutics Stock price

$14.14
-3.53 19.98% 1M
-1.50 9.59% 6M
-9.01 38.92% YTD
-9.24 39.52% 1Y
-0.86 5.73% 3Y
-0.86 5.73% 5Y
-0.86 5.73% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.75 5.04%
ISIN
US14179K1016
Symbol
CRGX
Sector
Industry

Key metrics

Market capitalization $650.83m
Enterprise Value $274.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.62
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-172.19m
Free Cash Flow (TTM) Free Cash Flow $-140.27m
Cash position $404.85m
EPS (TTM) EPS $-3.55
P/E forward negative
Short interest 14.23%
Show more

Is CARGO Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

CARGO Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a CARGO Therapeutics forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a CARGO Therapeutics forecast:

Buy
100%

Financial data from CARGO Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 6.79 6.79
-
-
-6.79 -6.79
-
-
- Selling and Administrative Expenses 29 29
-
-
- Research and Development Expense 130 130
-
-
-165 -165
-
-
- Depreciation and Amortization 6.79 6.79
-
-
EBIT (Operating Income) EBIT -172 -172
-
-
Net Profit -154 -154
-
-

In millions USD.

Don't miss a Thing! We will send you all news about CARGO Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CARGO Therapeutics Stock News

Neutral
GlobeNewsWire
12 days ago
SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.
Neutral
GlobeNewsWire
about 2 months ago
SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.
Neutral
GlobeNewsWire
about 2 months ago
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma
More CARGO Therapeutics News

Company Profile

Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Mateo, CA.

Head office United States
CEO Gina Chapman
Founded 2019
Website cargo-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today